Charm Therapeutics Raises $80 Million in Series B Financing to Advance Development of Best-In-Class Menin Inhibitor for Aml
New investors NEA and SR One lead round alongside existing investors OrbiMed, F-Prime, NVIDIA and Khosla Ventures CHARM’s AI-designed menin inhibitor overcomes resistance mutations with the potential to deliver superior efficacy, durability and safety; clinical development expected to start 1Q 26 Oncology leadership strengthened with appointment of former Syndax CEO......